Non-invasive DNA involves taking venous blood from a pregnant woman and using new generation DNA testing technology to test for free DNA fragments in the mother’s peripheral plasma and analyze the results to obtain genetic information about the fetus and detect the presence of Down syndrome (i.e., trisomy 21), as well as trisomy 18 and trisomy 13. The conclusion given by noninvasive DNA is a risk value, and a comparison of the criteria based on the risk value can lead to a low risk, a critical risk, or a high risk. If the risk is low, it generally means that the fetus is developing well and regular maternal checkups are needed later in life. If the non-invasive DNA result indicates a critical risk or high risk, it indicates that the fetus may have a congenital genetic disorder, but it cannot be used as a basis for confirmatory diagnosis, nor can the decision to keep the fetus be based on the non-invasive result. For non-invasive high risk further amniocentesis is required, which is the gold standard for confirming the diagnosis. If the amniocentesis determines that the fetus is fine, it can be retained. If the amniocentesis determines that the fetus has a chromosomal disorder, clinical advice is to abandon the pregnancy.